Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: The BEST study

Medical Care

Volumn 50, Issue 12, 2012, Pages 1076-1085

  Favato, Giampiero ^a   Baio, Gianluca ^b,c   Capone, Alessandro ^a   Marcellusi, Andrea ^d   Costa, Silvano ^e   Garganese, Giorgia ^f   Picardo, Mauro ^g   Drummond, Mike ^h   Jonsson, Bengt ⁱ   Scambia, Giovanni ^f   Zweifel, Peter ^j   Mennini, Francesco S ^d  

^a KINGSTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^h UNIVERSITY OF YORK   (United Kingdom)

ⁱ STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^j UNIVERSITY OF ZURICH   (Switzerland)

more..

Author keywords

Bayesian modeling; cost effectiveness; HPV vaccination; multicohort strategy; uncertainty

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BAYESIAN LEARNING; CONDYLOMA ACUMINATUM; CONTROL STRATEGY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE QUALITY; HEALTH ECONOMICS; HIDDEN MARKOV MODEL; HUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; BAYES THEOREM; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MARKOV CHAINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN; VACCINATION; YOUNG ADULT;

EID: 84870240117     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318269e06d     Document Type: Article

References (48)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
2. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(suppl 3):S35-S41. (Pubitemid 44293033)
3. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.
4. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001;11:598-603. (Pubitemid 33044469)
5. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41. (Pubitemid 46057835)
6. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821-832.
7. Mennini FS, Giorgi Rossi P, Palazzo F, et al. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol. 2009;112:370-376.
8. Mennini FS, Costa S, Favato G, et al. Anti-HPV vaccination: a review of recent economic data for Italy. Vaccine. 2009;27:A54-A61.
9. Favato G, Pieri V, Mills R. Cost-effective analysis of anti-HPV vaccination programme in Italy: a multi-cohort Markov model. March 2007. Available at: http://www.ssrn.com/abstract = 961847. Accessed January 1, 2011.
10. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine. 2007;25:5945-5957. (Pubitemid 47082460)
11. Briggs AH, Gray AM. Methods in health care service research- handling uncertainty in economic evaluations of healthcare intervention. BMJ. 1999;319:157-177.
12. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med. 2003;22:3687-3709. (Pubitemid 37483543)
13. Mennini F, Baio G, Montagnano G, et al. Governance of preventive health intervention and on time verification of its efficiency: the GIOVE study. BMJ Open. 2012;2:e000736.
14. Moscicki AB, Schiffman M, Kjaer S, et al. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24: S42-S51. (Pubitemid 44308674)
15. Maw RD, Reitano M, Roy M. An observational survey of patients with genital warts: perception regarding treatment and impact on lifestyle. Int J STD AIDS. 1998;9:571-578. (Pubitemid 28474812)
16. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet. 2007;369:1861-1868.
17. The FUTURE I Study Group. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356:1928-1943.
18. La Torre G, Chiaradia G, de Waure C, et al. Systematic review and meta-analysis of clinical trials on the efficacy of the quadrivalent HPV vaccine. HTA reports of quadrivalent anti-HPV vaccine, Gardasil. Ital J Public Health. 2009;2(suppl 2):S25-S32. [Italian].
19. Mennini FS, Baio G, Montagano G, et al. Governance of preventive health intervention and on time verification of its efficiency in a region of southern Italy. Health Technology Assessment International (HTAi) society, 7th annual meeting. Dublin, Ireland, 6th-9th June 2010. Abstract M5-18; p. 176-177.
20. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926-935.
21. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199:936-944.
22. Ronco G, Ghisetti V, Segnan N, et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer. 2005;41:297-305. (Pubitemid 40126963)
23. Canfell K, Barnabas R, Patnick J, et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91:530-536. (Pubitemid 39093574)
24. Centurioni MG, Puppo A, Merlo DF, et al. Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis. 2005;27:5-77.
25. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-1171. (Pubitemid 30451948)
26. Ronco G, Giorgi-Rossi P, Carozzi F, et al. New Technologies for Cervical Cancer screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7:547-555. (Pubitemid 43923665)
27. Giorgi Rossi P, Ricciardi A, Cohet C, et al. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health. 2009;9:71. Available at: http://www.biomedcentral.com/1471- 2458/9/71. Accessed January 1, 2011.
28. De Aloysio D, MiliffiL, Iannicelli T, et al. Intramuscular interferonbeta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection. Acta Obstet Gynecol Scand. 1994; 73:420-424. (Pubitemid 24164425)
29. French L, Nashelsky J. Clinical inquiries. What is the most effective treatment for external genital warts? J Fam Pract. 2002;51:313. (Pubitemid 34289364)
30. Italian Ministry of Health. List of prosthesis and technical aids provided within the framework of the national health service. Specialistic outpatient health care services. Available at: http://www.ministerosalute. it/imgs/C-17-bacheca-6-listaelencodocumenti-elenco0-listadocumenti-documento0- listafile-file0-linkfile.xls. Accessed January 1, 2011. [Italian].
31. List of prosthesis and technical aids provided within the framework of the national health service 2006. Lazio Region. Changes and additions to the DGR n. 439 of 21/07/2006. Available at: http://www.asplazio.it/asp-online/att- territoriale/files/sias/normativa/DGR562-5-09-06.pdf. Accessed January 1, 2011. [Italian].
32. List of prosthesis and technical aids provided within the framework of the national health service 2006 (second version of the ICD-IX). Emilia-Romagna. Available at: http://www.saluter.it/wcm/saluter/sanit aer/ssr/assistenza- territoriale/Dipartimento-cure-primarie/specialistica/linkallegati/nomenclatore/ allegati-2/nomencla-ICDIX-nov07.pdf. Accessed January 1, 2011. [Italian].
33. Costa S, Favato G. Evaluation of the economic impact produced by the prevention of events induced by the HPV 6-11virus types contained in the quadrivalent vaccine. January 2008. Available at: http://www.ssrn.com/abstract = 1080113. Accessed January 1, 2011.
34. Merito M, Largeron N, Cohet C, et al. Treatment patterns and associated costs for genital warts in Italy. Curr Med Res Opin. 2008;24:3175-3183.
35. Ferrandina G, Marcellusi A, Mennini FS, et al. Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecol Oncol. 2010;119:243-249.
36. Azzari C, Massai C, Poggiolesi C, et al. Cost of varicella-related hospitalizations in an Italian paediatric hospital: comparison with possible vaccination expenses. Curr Med Res Opin. 2007;23: 2945-2954.
37. AIRTum: Italian Network of Cancer Registries Work Group. Italian cancer figures-Report 2006. Incidence, mortality and estimates. I dati di incidenza e mortalitá dei Registri Tumori generali, 1998-2002. Epidemiol Prev, Suppl 2: 1-148, 2006. Available at: http://www.registritumori. it/cms/?q = Indice2006. Accessed January 1, 2011.
38. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457-472.
39. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196:1438-1446.
40. Mennini FS, Panatto D, Cristoforoni P, et al. The time-trade off approach to measure patients' preferences for health states associated with HPV-related pathologies: a multicenter study performed in Italy. Health Technology Assessment International (HTAi) society, 7th annual meeting. Dublin, Ireland, 6th-9th June 2010. Abstract M5-53; p. 192.
41. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health. 2001;55:123-125. (Pubitemid 32095198)
42. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224-227. (Pubitemid 39013284)
43. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008; 337:a769.
44. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513-524.
45. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884. Available at: http://www.bmj.com/content/339/bmj.b3884.full.pdf. Accessed January 1, 2011.
46. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858-6867.
47. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programmes. Med Decis Making. 2006;26:434-446. (Pubitemid 44410295)
48. Brisson M, Edmunds WJ. Economic evaluation of vaccination programmes: the impact of herd-immunity. Med Decis Making. 2003;23:76-82. (Pubitemid 36133362)